Ubiquinol, the active form of coenzyme Q10, is a dietary supplement studied mainly for heart function and fatigue. It is well tolerated; product quality varies widely. Ubiquinol-specific evidence is promising but thin: single trials or research groups suggest better symptoms in one heart-failure type, less fatigue and slower decline in a rare brain disease. Stronger heart-death evidence comes from ubiquinone, the older form; animal work shows no lifespan extension. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Plasma total CoQ10 | Above 2.5 µg/mL in advanced heart failure | Confirms absorption |
| INR (warfarin users only) | No established target; track change from own stable INR | Safety check; a fall changes warfarin dosing |
| HbA1c (people with diabetes) | 4.0–5.6% (standard reference range) | Expected to change; safety check on medication |
| NT-proBNP (people with heart failure) | No established target; track change from own baseline | Expected to change |
| Home blood pressure (people on blood-pressure drugs) | No established target; track change from own baseline | Safety check for additive lowering |
| Home glucose (people on glucose-lowering drugs) | Not specified in the ER | Safety check for additive lowering |
Cadence: Baseline plasma CoQ10 plus applicable safety tests; INR within 1–2 weeks of starting or stopping; blood pressure and glucose weekly for the first 4 weeks; plasma CoQ10 at 4–8 weeks once levels have plateaued; then every 6–12 months for CoQ10, HbA1c and NT-proBNP